首页 > 市场调查报告书 > 製药

以基因为基之药物开发

市场调查报告书

商品编码

1087024

基因编辑的全球市场预测(2022年～2027年)

Genome Editing Market - Forecasts from 2022 to 2027

出版日期: 2022年04月21日 | 出版商:

Knowledge Sourcing Intelligence | 英文 120 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

全球基因编辑的市场规模，从2020年的46亿400万美元，预计到2027年达到140亿5,400万美元，以17.29％的年复合成长率成长。

活用在农业和医疗领域，全球进行研究开发，对有解决各种问题的可能性的基因编辑技术的投资增加，预计在预测期间内的市场成长激增。此外，世界各地政府对提高作物的收穫量的基因编辑利用的支援，预计也是基因编辑市场的促进因素。

本报告提供全球基因编辑市场调查，市场概要，市场促进因素和阻碍因素，各技术、用途、终端用户、地区的分析，竞争情形，企业简介等资讯。

Genome editing is a method of making changes in a living organism's DNA and is used for improving crop yields, diagnosing and treating diseases, and for research purposes. The research and development in genome editing have been increasing worldwide as it is being used in the agriculture and healthcare sectors. Also, the investments in genome editing have been rising as the technique is being seen to have the potential to solve various problems, which is anticipated to surge the market growth during the forecast period. Furthermore, the support of various governments worldwide for the use of genome editing to improve crop yields is another prominent factor expected to drive the genome editing market. Moreover, the growing cases of cancer and other genetic disorders are surging the need for effective treatment and consequently leading to the market growth of genome editing.

The COVID-19 pandemic had a positive impact on the market as researchers developed new diagnostic tools based on CRISPR, a genome-editing technique, for diagnosing COVID-19 patients. This led to a positive impact on the genome editing market and increased the expected growth rates of the genome editing market in 2020 and 2021. As the spread of coronavirus continues to affect the world with its new waves and variants, the pandemic is projected to have a positive impact on the genome editing market in the coming years as well.

Growing cases of cancer and other genetic disorders

The cases of cancer and other genetic disorders have been increasing globally. The growing interest in genome editing for the treatment of cancer and several genetic disorders is anticipated to propel the growth of the genome editing market during the forecast period. NIH researchers have recently, in January 2021, found and recognized a new genetic disorder called linkage-specific-deubiquitylation-deficiency-induced embryonic defects syndrome (LINKED) that causes delays in development and hinders the proper formation of heart, facial features, and brain. Such identifications of new genetic disorders also contribute to the rising cases of genetic disorders. Furthermore, cancer cases have been proliferating. According to data from the International Agency for Research on Cancer (IARC), the number of cancer cases in the United Kingdom (England and Wales) has increased from 138,577 in 2010 to 156,444 in 2017 for males and from 130,674 in 2010 to 149,239 in 2017 for females. As per IARC, the number of cancer cases in Europe is projected to jump from 4.398 million in 2020 to 5.323 million in 2040, witnessing an increase of around 21%. In North America, the cases of cancer are projected to reach 3.525 million in 2040, increasing from 2.557 million in 2020, growing by nearly 38%. This is expected to have a positive impact on the genome editing market in the coming years, owing to an increasing need for better cancer treatments.

Rising investments and research in genome editing

In September 2021, the UK government announced its plans to support gene editing in agriculture to support the country's farmers in growing better and more productive crops. The government is making research and development easier. It also aims to make the necessary measures for genome-edited products to reach safely and responsibly to the market. Furthermore, the government of China is backing the use of CRISPR, a genome-editing technique, to improve the food supply in the country. In 2017, the state-owned company of China named ChemChina acquired Syngenta, a Switzerland-based agribusiness company working with CRISPR with an extensive research and development team. China spent $43 billion on the deal, which is the largest amount ever spent by China on buying a foreign company. The investments in genome editing are expected to grow further in the coming years, along with rising research and development, and are anticipated to boost the genome editing market growth during the forecast period.

North America to dominate the global market

Geographically, the North American region is anticipated to hold a significant market share owing to the large investments being made in the region in the field of genome editing. The Asia Pacific region is anticipated to witness substantial growth due to the surging cases of genetic disorders and cancer, along with higher spending on healthcare and research. As per the data from IARC, the number of cancer cases in Asia is projected to grow by more than 59%. Furthermore, the use of CRISPR has been increasing substantially in China, which is further expected to contribute to the market growth in the Asia Pacific.

Segmentation

By Technology

CRISPR

TALEN

ZFN

Others

By Application

Cell Line Engineering

Animal Genetic Engineering

Plant Genetic Engineering

By End-User

Academic & Government Research Institutes

Biotechnology & Pharmaceutical Companies

Contract Research Organizations

By Geography

North America

USA
Canada
Mexico

South America

Brazil
Argentina
Others

Europe

Germany
France
UK
Others

Middle East and Africa

Saudi Arabia
UAE
Others

Asia Pacific

China
India
Japan
South Korea
Taiwan
Thailand
Indonesia
Others

1. Introduction

1.1. Market Definition
1.2. Market Segmentation

2. Research Methodology

2.1. Research Data
2.2. Assumptions

3. Executive Summary

3.1. Research Highlights

4. Market Dynamics

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of End-Users
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. Genome Editing Market Analysis, by Technology

5.1. Introduction
5.2. CRISPR
5.3. TALEN
5.4. ZFN
5.5. Others

6. Genome Editing Market Analysis, by Application

6.1. Introduction
6.2. Cell Line Engineering
6.3. Animal Genetic Engineering
6.4. Plant Genetic Engineering

7. Genome Editing Market Analysis, by End-User

7.1. Introduction
7.2. Academic & Government Research Institutes
7.3. Biotechnology & Pharmaceutical Companies
7.4. Contract Research Organizations

8. Genome Editing Market Analysis, by Geography

8.1. Introduction
8.2. North America
- 8.2.1. USA
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. Germany
- 8.4.2. France
- 8.4.3. UK
- 8.4.4. Others
8.5. Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Others
8.6. Asia Pacific
- 8.6.1. China
- 8.6.2. India
- 8.6.3. Japan
- 8.6.4. South Korea
- 8.6.5. Taiwan
- 8.6.6. Thailand
- 8.6.7. Indonesia
- 8.6.8. Others

9. Competitive Environment and Analysis

9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix

10. Company Profiles

10.1. Thermo Fisher Scientific Inc.
10.2. Merck & Co., Inc.
10.3. Horizon Discovery Group plc
10.4. GenScript
10.5. Sangamo Therapeutics, Inc.
10.6. Integrated DNA Technologies, Inc.
10.7. Lonza Group Ltd.
10.8. BEX Co., LTD.
10.9. OriGene Technologies, Inc.
10.10. Transposagen Biopharmaceuticals, Inc.

02-2729-4219

+886-2-2729-4219

License/价格

基因编辑的全球市场预测(2022年～2027年)

Genome Editing Market - Forecasts from 2022 to 2027

目录

第1章简介

第2章调查手法

第3章摘要整理

第4章市场动态

第5章基因编辑市场分析:各技术

第6章基因编辑市场分析:各用途

第7章基因编辑市场分析:各终端用户

第8章基因编辑市场分析:各地区

第9章竞争环境与分析

第10章企业简介